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Abstract
Gene signatures have been developed for estrogen receptor–positive breast cancer to complement pathological
factors in providing prognostic information. The 70-gene and the 21-gene signatures identify patients who may
not require adjuvant chemotherapy. Gene signatures in triple-negative disease and HER2-positive disease have
not been fully developed yet, although studies demonstrate heterogeneity within these subgroups. Further research
is needed before genotyping will help in making clinical decisions in triple-negative and HER2-positive disease.
Molecular subtyping of breast cancer led to define luminal, basal, and HER2-enriched subtypes, which have specific
clinical behavior. This approach may lead to identify new subgroups requiring specific therapies. Standardization of
techniques will be required to translate investigations to the clinic.
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Introduction
Breast cancer is a major health issue in developed countries. Early
diagnosis and the use of adjuvant therapies have contributed to improve
survival, but still 87,000 women died of breast cancer in the European
Union in 2011 [1]. Further improvement in outcome could be
achieved through a more adequate use of existing therapies. In this
context, gene signatures have been incorporated into clinical practice
to complement traditional pathology and guide clinical decisions.
The information provided by prognostic or predictive factors is
important if it helps in making clinical decisions. Regarding the manage-
ment of early breast cancer, the indication for adjuvant radiation therapy
depends on classic pathological factors, whereas the need for hormonal
therapy and adjuvant trastuzumab depends on the results of immuno-
histochemistry. However, the indication for adjuvant chemotherapy is
more complex, because no single biomarker predicts that the patient will
benefit from this kind of treatment. Gene signatures are useful because
they may identify patients who will require adjuvant chemotherapy.
This paper will deal with the accepted indications of gene signa-
tures in the management of breast cancer, with an emphasis on
strengths and limitations of available tools. It will also offer a glimpse
into future applications.
Gene Signatures in ER+ Disease
In patients with ER+ disease, adjuvant chemotherapy is recom-
mended in the presence of risk factors (young age, positive lymph
nodes, tumor size of more than 1 cm, or poorly differentiated histology/
high proliferation index). However, if the patient presents with just
one of these factors, the decision to administer chemotherapy is not
obvious. The widespread use of adjuvant chemotherapy, even in
women with an intermediate risk of relapse, has greatly contributed
to improve prognosis in the last decades but at the cost of over-
treatment in many patients [2]. Classic parameters have been inte-
grated in software applications—such as Adjuvant! Online [3]—to
help doctors in calculating risk of relapse and benefit from adjuvant
therapy. However, uncertainty remains in many cases even with the
use of this software.
Gene signatures can complement classic prognostic factors to
obtain more accurate prognostic information. The 70-gene signa-
ture (MammaPrint; Agendia, Amsterdam, The Netherlands) and the
21-gene signature (OncoType; Genomic Health, Redwood City, CA)
are being used in selected patients with early ER+ disease to identify
those women that will be cured even if they do not receive adjuvant
chemotherapy [4,5]. These signatures have been extensively studied
and are widely used in Europe and in USA [6–8]. The National Cancer
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Comprehensive Network guidelines indicate that the 21-gene signature
can be considered in women with tumors >0.5 cm, HER2-negative
disease, and either N0 or N1mi (micrometastasis) disease [9]. The
National Cancer Comprehensive Network recommendations do not
mean that all tumors with such characteristics should be studied with
a multigene product: Doctors should select cases within these groups if
they doubt about the need for adjuvant chemotherapy.
Both the 70-gene and the 21-gene signatures have predictive, in
addition to prognostic, value. This means that, in women allocated
to high-risk groups, adjuvant chemotherapy significantly improves
disease-free survival, as opposed to those in low-risk groups
[10,11]. Analyses confirming the additional predictive value of gene
signatures were based on clinical trials including anthracyclines but
not taxanes, although it is reasonable to think that similar conclu-
sions can be drawn with regard to current chemotherapy schemes.
Limitations of the 70-gene and the 21-gene signatures include
price, the requirement to send samples to a reference center, and,
in the case of OncoType, the existence of an intermediate group
for which the value of adjuvant chemotherapy is not clear. The clinical
trial TailorX, which has completed accrual, will define if patients in
the intermediate-risk group do benefit from chemotherapy. Finally, in
the case of very small tumors, it may be difficult to isolate enough
material to perform the test.
There are other tools designed for ER+ tumors. MapQuant Dx
(Ipsogen, Marseille, France) is a 97-gene genomic grade index that
splits grade 2 tumors into two categories: one with an outcome similar
to that of grade 1 tumors and the other similar to grade 3 [12]. Patients
in the favorable group could be treated without chemotherapy. It is
microarray based and requires freshly prepared tissue. The Breast
Cancer Index (BioTheranostics, San Diego, CA) is a seven-gene assay
that identifies a low-risk group of patients that can be safely treated
with adjuvant tamoxifen and no chemotherapy [13]. It is based on
quantitative reverse transcription–polymerase chain reaction (PCR)
and can be used in paraffin-embedded tissue. Other signatures have
been described [14]. Experience with these products is more limited
than with the 21-gene and the 70-gene signatures.
There are some unmet needs in the field of ER+ breast cancer. Gene
signatures have been developed for ductal carcinoma but not for lobu-
lar carcinoma. Some studies suggest that, although lobular and ER+
ductal invasive carcinomas share common genomic alterations, the for-
mer has some specific molecular features [15–17]. On the other hand,
gene signatures predict relapses in the first 5 to 10 years of follow-up
but less reliably in the long term, maybe because tumors with such a
long natural history have distinct, hitherto unknown genetic features.
Gene Signatures in Triple-Negative Disease
Patients with triple-negative breast cancer do not have the option to
receive therapy with hormonally directed agents, so chemotherapy
remains the standard of care in this setting. Two uncommon varieties
of breast cancer—medullary and adenoid cystic carcinoma—are triple-
negative tumors associated with an excellent prognosis [18,19]; their
diagnosis relies on morphological criteria. With these two exceptions,
triple-negative tumors usually have a high proliferation rate and poor
prognosis, so it is unlikely that gene signatures may identify a favorable
group of patients who could forgo adjuvant chemotherapy. Indeed, no
signatures have been validated that demonstrate this. Predictors devel-
oped in ER+ disease may not function in the triple-negative context
because the predominant processes linked to outcome differ between
subtypes. For instance, proliferation is an important feature in ER+
disease, whereas immune responses may be more determinant in
estrogen receptor–negative disease [20].
The possibility to predict response to chemotherapy has attracted
considerable attention in the field of triple-negative disease. Some
studies have focused on one drug or combination of drugs in the neo-
adjuvant setting, where the main parameter of response is the rate of
pathological complete response to chemotherapy [21–23]. However,
defining sensitivity in terms of complete response has been an elusive
goal. One possible explanation is that there may be multiple mecha-
nisms of drug resistance in a series of tumors, so one single signature
will not identify all of them [24].
Gene profiling has also been used to subdivide triple-negative dis-
ease into distinct entities. For instance, a ratio of high B-cell and low
interleukin-8 (IL-8) metagenes has been associated with good prognosis
in this population [25]. In another study, a group of 14 genes identified
patients with a good outcome in the absence of adjuvant therapy [26].
In a supervised analysis of publicly available data sets or triple-negative
disease, a group of genes related to inflammation and angiogenesis
provided prognostic information; the combination of a prognostic
profile and a B-cell metagene also predicted response to neoadjuvant
chemotherapy [27]. Other studies have demonstrated that triple-
negative disease is a heterogeneous group, which may encompass
different molecular entities [26,28–31]. For instance, one study
analyzed gene expression profiles from 21 breast cancer data sets
and identified six triple-negative subtypes. Cell line models represen-
tative of these models were also identified, which allowed targeting
driver pathways with specific drugs. This experiment served as proof
of concept that gene expression analysis can inform therapy selection.
Subclassifications of triple-negative breast cancer have not yielded
therapeutic advantages so far but could do so in the future. Some
triple-negative tumors have an aberrant BRCA1 pathway, which could
allow therapy with poly (adenosine diphosphate [ADP]-ribose) poly-
merase inhibitors. However, clinical studies with poly(ADP-ribose)
polymerase inhibitors have yielded disappointing results in breast
cancer so far [32,33]. These poor results suggest that further investiga-
tion is required to find a role for these drugs. Platinum-based therapy
could also be useful in triple-negative disease, particularly in cases with
concomitant BRCA1 mutation [34]. On the other hand, as epidermal
growth factor receptor (EGFR) is part of the basal cluster, it could be
a target in this subgroup of breast cancer. One clinical trial of chemo-
therapy with or without cetuximab (an anti-EGFR antibody) suggested
that inhibition of EGFR yields a benefit when the pathway is de-
activated [35]. Finally, the melanoma antigen family A could define
a very aggressive subgroup of triple-negative breast cancer, particularly
in the absence of immune infiltration in the tumor microenvironment
[36]. This finding suggests that triple-negative tumors with melanoma
antigen family A expression might benefit from drugs that enhance the
immune response.
Any gene signature for triple-negative disease should be prospec-
tively tested in the clinic before widespread use, in the same way that
the 70-gene and the 21-gene signatures were studied in ER+ disease.
Once a gene tool would demonstrate utility to answer a clinically
relevant question, it could be incorporated into daily practice.
Gene Signatures in HER2-Positive Disease
Virtually all patients with HER2-positive disease receive chemo-
therapy plus anti-HER2 therapy, either in the adjuvant, the neo-
adjuvant, or the metastatic setting. The combination of chemotherapy
with two anti-HER2 drugs (for instance, trastuzumab + lapatinib or
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trastuzumab + pertuzumab) increases response rates in neoadjuvant
therapy. This strategy, however, increases costs, so it should be lim-
ited to those patients who are less likely to benefit from single-agent
therapy. Considerable effort has been devoted to identify mech-
anisms of resistance to trastuzumab [37–39]. A few studies have
dealt with gene profiling to detect resistance to the drug [40,41],
but validated signatures that can be taken to the clinic have not
been described.
HER2-positive breast cancer is a heterogeneous disease. In general,
response to systemic therapy is poorer in ER+ disease than in ER−
[42], although prognosis is better in the former. In a retrospective
study, the 70-gene signature identified a subgroup of HER2+ early
breast cancer with a favorable long-term outcome, which suggests
genetic heterogeneity within the HER2+ population [43]. In another
study, a 158-gene predictor identified patients with better and worse
outcome across multiple data sets [44]. Further insight into the molec-
ular biology of these tumors might lead to the description of new
therapeutic targets in specific subtypes of HER2-positive tumors. On
the other hand, some patients with metastatic disease survive for pro-
longed periods of time after treatment with trastuzumab; identification
of these patients could have interest not only in advanced disease but
also in the adjuvant setting.
Molecular Subtyping
The molecular classification of breast cancer created in the year 2000
established several subgroups of tumors, such as luminal A, luminal
B, basal-like, and HER2 enriched [45]. This classification has greatly
influenced the way in which breast cancer is currently regarded
by clinicians and investigators alike. It is important to understand
the difference between subtypes defined by immunohistochemistry
and gene data sets: for instance, although many ER+ tumors cor-
respond to the luminal A subtype, there is overlapping with other
subtypes. The same happens with triple-negative and basal-like dis-
ease or the HER2 subgroup, so terminology should be accurate in
scientific communication.
The molecular subgroups harbor prognostic value, because patients
with luminal A tumors have better prognosis than patients with other
tumor subtypes (particularly luminal B and basal-like). On the con-
trary, poor prognosis subtypes respond better to chemotherapy com-
pared to luminal A tumors, so the classification also offers predictive
information [46]. Recent evidence indicates that the HER2-enriched
subtype has a special sensitivity to anthracyclines, whereas luminal
and basal-like tumors obtain a similar benefit from an anthracycline-
and a non–anthracycline-based adjuvant chemotherapy [47]. Further
studies are required to corroborate these results.
The molecular classification of breast cancer has not contributed
to modify standard therapy in any subgroup of patients. For instance,
the administration of trastuzumab or lapatinib is determined by the
results of immunohistochemistry or fluorescence in situ hybridization
(FISH) for HER2 and no study has demonstrated that limiting the
use of these drugs to patients with the HER2-enriched subtype would
yield better results. Moreover, a basal-like or luminal B tumor with
HER2 overexpression should also receive anti-HER2 therapy. Like-
wise, a claudin-low subtype that is associated with a poor outcome
has recently been described [46], but optimal therapy for this subtype
has not been defined. Studies comparing classic and molecular criteria
to select treatment would be required to know if new technologies
would allow a more rational use of current therapeutic options.
Two commercial applications offer molecular subtyping at this
time (PAM50, ARUP, Salt Lake City, UT and BluePrint, Agendia).
Attempts have been made with PAM50 in patients with ER+ disease
to identify those who do well without adjuvant chemotherapy, in a
similar way to the 70-gene and the 21-gene signatures. A combined
prognostic marker that includes the proliferation genes of PAM50
and tumor size identifies a subpopulation with an excellent outcome
if treated with hormonal therapy alone [48].
New Technologies
Currently available tools are based on microarrays or quantitative
reverse transcription–PCR platforms. The development of massive
parallel sequencing can provide more extensive information about
genomic abnormalities in breast cancer. As the cost of sequencing
is decreasing rapidly, tumors can be sequenced in real time at the
clinic, if and when the information is considered clinically useful
[49]. However, further refinement of this technology is needed
before its results can be used in the clinic. For the moment, massive
Figure 1. Current clinical use of gene signatures in ER+ disease. Classic prognostic factors include tumor size, lymph node infiltration,
grade of differentiation, and age.
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sequencing may be more suitable for investigational purposes than
for daily practice.
Proteomics and metabolomics are promising technologies that are
already providing interesting results in the biomarker discovery arena.
Again, these “omics” will require further development in terms of
standardization and reproducibility before they are incorporated into
the clinic.
The use of all new technologies will also depend on bioinformatics
and statistic tools to analyze massive amount of data. Likewise, large
sample collections and cooperative/multidisciplinary networks will be
required to draw valid conclusions. The recent METABRIC results
are a good example in this direction [50]. This consortium analyzed
2000 tumors by integrating views of the genome and transcriptome:
10 breast cancer subtypes were described and validated, including a
high-risk estrogen receptor–positive 11q13/14 cis-acting subgroup
and a favorable prognosis subgroup devoid of copy number aber-
rations. This study provides an excellent example of how recent tech-
nical breakthroughs bring new opportunities to clinical research,
allowing the analysis of cancer samples from multiple perspectives,
from genomics to proteomics.
Need for Standardization
Reproducibility of classic markers—basically hormonal receptors and
HER2—is a major issue in daily practice and in clinical investigation
[51–53]. Lack of reproducibility is accepted only because immuno-
histochemistry is cheap and widely available, but it is hard to believe
that genomic assays were approved for clinical use with a 20% dis-
cordance rate. The 70-gene and the 21-gene signatures have shown
excellent concordance when repeated on different days by different
technicians [54,55], which is probably due to the fact that these gene
tests are performed in centralized laboratories. If high-throughput
techniques were to be performed locally, reproducibility should be
ensured both in large hospitals processing a lot of samples and in
small centers.
A Glimpse to the Future
High-throughput technologies have a huge potential to help in the
management of breast cancer, but so far their use has been limited. While
these tools are not meant to replace the standard pathological workup,
they could provide important complementary information in many cases.
In triple-negative breast cancer, gene profiling is unlikely to find
patients who do not need adjuvant chemotherapy, but it could serve
a different purpose. Our group performed a discovery PCR study in
samples from patients with ER-negative disease who had received
adjuvant chemotherapy [56]. A five-gene score splits this population
into two groups, one with excellent metastasis-free survival and the
other with a 50% chance of distant relapse. This was a small study
that is focused in a different target population, but it demonstrates
that gene profiling can be applied to patients treated with adjuvant
chemotherapy and opens new possibilities. A similar approach could
be used in patients with triple-negative disease treated with chemo-
therapy or in those with HER2+ disease receiving chemotherapy plus
trastuzumab. Patients in favorable groups could be safely treated with
standard chemotherapy ± trastuzumab, but patients in the poor prog-
nosis group would be ideal candidates for clinical trials with new
drugs (Figure 1). By excluding low-risk patients, such trials would
be enriched in a population that would be more likely to benefit
from the new drug, and as a consequence, fewer patients should be
included. In addition, the poor prognosis population could undergo
a more thorough follow-up schedule than the general population
with breast cancer. Follow-up schedules have become simpler in recent
decades but could be modified for the early detection of relapse in
selected patients.
Molecular subtyping of breast cancer has changed our view of this
disease but has not been used to make clinical decisions so far. The
greatest interest of the molecular classification is the possibility to
subdivide breast cancer into entities that require specific treatments.
The thorough analysis of subtypes may lead to the detection of
targetable molecular defects. If a new drug effectively targets a gene
marker, the detection of such marker should be incorporated to the
standard pathological study. As a consequence, the molecular classi-
fication will evolve over time: Indeed, the definition of subtypes has
slightly changed since the first description and will continue to do so.
Additionally, the molecular classification of breast cancer could be
used to tailor follow-up strategies, if it identifies tumors with higher
chance of dissemination. In this regard, genes involved in lung and
brain dissemination of breast cancer have been described [57,58].
Considering these possibilities, it would be possible to build a two-
step process to make decisions in the management in early stage breast
cancer (Figure 1). Standard pathological procedures could be comple-
mented with gene signatures—different for ER+ and ER− disease—to
identify patients likely to be cured with standard systemic treatment.
Patients unlikely to be cured with that approach would require addi-
tional treatment. The use of predictive signatures would be fully
justified in unfavorable subgroups.
Conclusions
Gene signatures will be incorporated into clinical practice if they help
in making clinical decisions. For the moment, some of these tools are
being used in ER+ early stage disease to decide whether the patient
will forgo adjuvant chemotherapy. In the case of triple-negative or
HER2+ tumors, gene signatures could provide information about
the best way to administer available drugs, or they could also identify
subgroups of patients to be treated with new specific therapies. Clinical
studies will have to be done to demonstrate that these hypothetical uses
will improve patients’ outcome.
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